-- オリックス（東証：8591）は、米国の通信インフラ企業ネットワーク・コネックスの親会社であるIX NTIホールディングスの株式すべてを、オリンパス・パートナーズ傘下の特別目的会社に売却することで合意した。これは、火曜日に東京証券取引所に提出された書類で明らかになった。 この取引により、オリックス・キャピタル・パートナーズからIX NTIホールディングスへ100%の所有権が移転する。ただし、米国の独占禁止法に基づく承認を含む、各種規制当局の承認が必要となる。 オリックスは、売却時期と財務への影響は依然として不透明であり、売却益は取引完了条件と為替変動によって左右されるとしている。
Related Articles
Asia
Biocytogen Pharmaceuticals Turns to Profit in Q1
Biocytogen Pharmaceuticals (Beijing) (HKG:2315) recorded an attributable profit of 104 million yuan in the first quarter of 2026, compared with an attributable loss of 13.2 million yuan a year prior, according to a Monday Hong Kong bourse filing.Earnings per share stood at 0.23 yuan, compared with a loss per share of 0.03 yuan in the corresponding period of the previous fiscal year.Operating revenue jumped 74% in the three months to 433.1 million yuan from 249.3 million yuan in the year-ago period, driven by a substantially higher revenue contribution from pharmacology and efficacy services and animal models.The pharmaceutical company attributed the higher profit mainly to revenue growth and improved operating efficiency amid expense management.
$HKG:2315
Oil & Energy
Market Chatter: LNG Carrier Orders Surge as Global Output Defies Iran War Tensions
Global demand for liquefied natural gas carriers is rebounding sharply in 2026, despite the ongoing US-Iran conflict, Reuters reported Monday, citing analysts and industry experts.Analysts report that surging LNG production and a transition toward high-efficiency vessels are fueling the recovery.According to the report, Shipbuilders in South Korea and China have already secured 35 new build contracts in Q1 alone.The resurgence in construction comes despite the escalating US-Iran war, which has choked the Strait of Hormuz and raised fears of a prolonged shipping downturn.However, market experts suggest that the need for modern, fuel-efficient tonnage is outweighing immediate freight rate concerns, it said.These new vessels, which cost between $250 million and $260 million and take over three years to complete, are increasingly necessary as older, steam-propelled tankers are scrapped at record rates to meet stricter global emissions regulations.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Research
Canaccord Genuity Initiates Coverage on Structure Therapeutics With Buy Rating, $101 Price Target
Structure Therapeutics (GPCR) has an average rating of Buy and mean price target of $108.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$GPCR